p.164 抽出テキスト

apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 2014; 48: 565-575. PMID: 24951377 297. Kim K, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry Investigators. Risk factors for major bleeding during prolonged anticoagulation therapy in patients with venous thromboembolism: From the COMMAND VTE Registry. Thromb Haemost 2019; 119: 1498-1507. PMID: 31230344 298. Nishimoto Y, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry Group. Validation of the VTE-BLEED score's long-term performance for major bleeding in patients with venous thromboembolisms: From the COMMAND VTE registry. J Thromb Haemost 2020; 18: 624-632. PMID: 31785073 299. Yamashita Y, Morimoto T, Kimura T. Venous thromboembolism: Recent advancement and future perspective. J Cardiol 2022; 79: 79- 89. PMID: 34518074 300. Cohen H, Arachchillage DR, Middeldorp S, et al. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14: 1673- 1676. PMID: 27346676 301. Zhao Y, Arya R, Couchman L, et al. Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations? Blood 2020; 136: 1783-1785. PMID: 32488251 302. Yamashita Y, Hira D, Morita M, et al. Potential treatment option of rivaroxaban for breastfeeding women: A case series. Thromb Res 2024; 237: 141-144. PMID: 38593524 303. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002; 88: 407-414. PMID: 12353068 304. Lee CH, Cheng CL, Lin LJ, et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J 2011; 75: 1998-2004. PMID: 21697611 305. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107 Suppl: I22-I30. PMID: 12814982 306. Stein PD, Matta F, Musani MH, et al. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med 2010; 123: 426-431. PMID: 20399319 307. Yamashita Y, Yoshikawa Y, Morimoto T, et al. COMMAND VTE Registry Investigators. The association of recurrence and bleeding events with mortality after venous thromboembolism: From the COMMAND VTE Registry. Int J Cardiol 2019; 292: 198-204. PMID: 31239211 308. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 326: 515-518. PMID: 2863541 309. deleted in proof. 310. Mo M, Fukuda I, Nakamura M, et al. J’xactly Investigators. Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J'xactly, in Japan. Phlebology 2023; 38: 4-15. PMID: 36433754 311. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 Suppl: e419S-e496S. PMID: 22315268 312. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149: 315-352. PMID: 26867832 313. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133 Suppl: 454S-545S. PMID: 18574272 314. National Clinical Guideline Centre (UK). Venous thromboembolic diseases: The management of venous thromboembolic diseases and the role of thrombophilia testing (NICE Clinical Guidelines #144). Royal College of Physicians (UK), 2012. 315. Horner D, Hogg K, Body R, et al. The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial. Chest 2014; 146: 1468-1477. PMID: 25010443 316. Righini M, Galanaud JP, Guenneguez H, et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol 2016; 3: e556-e562. PMID: 27836513 317. Shimabukuro N, Mo M, Hashiyama N, et al. Clinical course of asymptomatic isolated distal deep vein thrombosis of the leg: A single-institution study. Ann Vasc Dis 2019; 12: 487-492. PMID: 31942206 318. 山田典一,八巻隆,岩田博英,他.本邦における下腿限局型深部静脈血栓症に対する治療の現状(日本静脈学会サーベイ調査研究報告).静脈学 2013;24;211. 319. 榛沢和彦,伊倉真衣子.日本における災害の無い地域(災害対照地)

の下腿深部静脈血栓の陽性率.血栓止血誌 2022;33:675-682. 320. Singh K, Yakoub D, Giangola P, et al. Early follow-up and treatment recommendations for isolated calf deep venous thrombosis. J Vasc Surg 2012; 55: 136-140. PMID: 21982332 321. Ageno W, Bertù L, Bucherini E, et al. RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ 2022; 379: e072623. PMID: 36520715 322. Xiong W, Yamashita Y, Morimoto T, et al. ONCO DVT Study Investigators. Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study. J Thromb Haemost 2024; 22: 3542-3551. PMID: 39284385 323. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022; 8: 11. PMID: 35177631 324. Mahajan A, Brunson A, White R, et al. The epidemiology of cancer-associated venous thromboembolism: An update. Semin Thromb Hemost 2019; 45: 321-325. PMID: 31041801 325. Raskob GE, Wendelboe AM, Campbell J, et al. Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost 2022; 20: 2366-2378. PMID: 35830203 326. Nose T, Imamura Y, Ohata S, et al. Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients. Int J Hematol 2021; 114: 319-324. PMID: 34091877 327. Ohashi Y, Ikeda M, Kunitoh H, et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol 2020; 50: 1246- 1253. PMID: 32715307 328. Suzuki T, Hori R, Takeuchi K, et al. Venous Thromboembolism in Japanese patients with pancreatic cancer. Clin Appl Thromb Hemost 2021; 27: 10760296211051766. PMID: 34730013 329. Sakamoto J, Yamashita Y, Morimoto T, et al. COMMAND VTE Registry Investigators. Cancer-associated venous thromboembolism in the real world From the COMMAND VTE Registry. Circ J 2019; 83: 2271-2281. PMID: 31548438 330. Mountain D, Jacobs I, Haig A. The VIDAS D-dimer test for venous thromboembolism: a prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice. Am J Emerg Med 2007; 25: 464-471. PMID: 17499668 331. Wu J, Fu Z, Liu G, et al. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine (Baltimore) 2017; 96: e7062. PMID: 28640083 332. Yang M, Qi J, Tang Y, et al. Increased D-dimer predicts the risk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: A systematic review and meta-analysis. Thromb Res 2020; 196: 410-413. PMID: 33022489 333. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907. PMID: 18216292 334. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-5382. PMID: 20829374 335. Akasaka-Kihara F, Sueta D, Ishii M, et al. Validation of the Khorana venous thromboembolism risk score in Japanese cancer patients. JACC Asia 2021; 1: 259-270. PMID: 36338156 336. Lee AY, Levine MN, Baker RI, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146- 153. PMID: 12853587 337. Raskob GE, van Es N, Verhamme P, et al. Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-624. PMID: 29231094 338. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017-2023. PMID: 29746227 339. Agnelli G, Becattini C, Meyer G, et al. Caravaggio Investigators.

Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382: 1599-1607. PMID: 32223112